First-in-Class or Too Risky? The Future of Novel Targets

Please mark your calendars for this year’s BioInnovate Program Series celebrating life science innovators from Weill Cornell Medicine as well as startup representatives from Cornell University and Cornell Tech.

Join leading investors and industry representatives from organizations including Healthwrx, EpiVax, Fusion Fund, LabyRx, Scion Life Sciences, L.E.K. Consulting, Qiming Venture Partners, and Regeneron for a dynamic series of conversations and events.

With more than 21,000 drug programs in the global R&D pipeline, you might expect a surge in new biological targets. Instead, novel targets entering development have fallen from ~100 per year a decade ago to about 30 in 2024, while 25% of drug-target pairs focus on just 38 well-known targets.

As AI, new modalities, and cell therapies expand the frontier of drug discovery, what does it take to build the chain of evidence investors and industry partners need to back a novel target? Join our upcoming panel to find out.

Register here.